<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>30(5)</volume><submitter>Ngo BT</submitter><funding>The Rose Salter Medical Research Foundation</funding><pubmed_abstract>&lt;b>Background:&lt;/b> COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.&lt;b>Methods:&lt;/b> We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.&lt;b>Results:&lt;/b> As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients</pubmed_abstract><journal>Expert opinion on investigational drugs</journal><pagination>505-518</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8074648</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The time to offer treatments for COVID-19.</pubmed_title><pmcid>PMC8074648</pmcid><pubmed_authors>Chaudhary P</pubmed_authors><pubmed_authors>Hanna DL</pubmed_authors><pubmed_authors>Bello Rivero I</pubmed_authors><pubmed_authors>Ngo BT</pubmed_authors><pubmed_authors>Smogorewski M</pubmed_authors><pubmed_authors>Varon J</pubmed_authors><pubmed_authors>Dube M</pubmed_authors><pubmed_authors>Peschanski N</pubmed_authors><pubmed_authors>Thomadsen R</pubmed_authors><pubmed_authors>Griffin D</pubmed_authors><pubmed_authors>Confalonieri M</pubmed_authors><pubmed_authors>In G</pubmed_authors><pubmed_authors>Nanda N</pubmed_authors><pubmed_authors>Armstrong A</pubmed_authors><pubmed_authors>Hayem G</pubmed_authors><pubmed_authors>Soriano V</pubmed_authors><pubmed_authors>Vinjevoll EH</pubmed_authors><pubmed_authors>Ditmore S</pubmed_authors><pubmed_authors>Brennan-Rieder D</pubmed_authors><pubmed_authors>Mitja O</pubmed_authors><pubmed_authors>Sawcer DE</pubmed_authors><pubmed_authors>Arkfeld D</pubmed_authors><pubmed_authors>Turkia M</pubmed_authors><pubmed_authors>Iglesias J</pubmed_authors><pubmed_authors>Dasgupta R</pubmed_authors><pubmed_authors>Shapiro L</pubmed_authors><pubmed_authors>Marik P</pubmed_authors><pubmed_authors>Piccirillo MC</pubmed_authors><pubmed_authors>Hung IF</pubmed_authors><pubmed_authors>Peng D</pubmed_authors><pubmed_authors>Kory P</pubmed_authors><pubmed_authors>Lobo-Ferreira A</pubmed_authors><pubmed_authors>Ehresmann G</pubmed_authors><pubmed_authors>Sattler F</pubmed_authors><pubmed_authors>Mussini C</pubmed_authors><pubmed_authors>Campese VM</pubmed_authors><pubmed_authors>Rendell M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The time to offer treatments for COVID-19.</name><description>&lt;b>Background:&lt;/b> COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.&lt;b>Methods:&lt;/b> We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.&lt;b>Results:&lt;/b> As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2026-04-19T03:21:03.488Z</modification><creation>2022-02-11T14:32:19.35Z</creation></dates><accession>S-EPMC8074648</accession><cross_references><pubmed>33721548</pubmed><doi>10.1080/13543784.2021.1901883</doi></cross_references></HashMap>